InSilico Medicine Cayman TopCo (InSilico) reported several capital movements between 11 and 13 November 2026, according to its Next Day Disclosure Return filed on 13 November.
New share issuance • 58,706 ordinary shares were issued through the exercise of employee stock options from the company’s Pre-IPO Equity Incentive Plans. • The options were exercised in three tranches at prices ranging from HK$3.25 to HK$3.30 per share, generating cash proceeds of roughly HK$0.19 million. • These new shares represented a 0.0100 % increase versus the opening issued share balance on 9 November.
Share repurchase • On 13 November, the company repurchased 300,000 ordinary shares on the Hong Kong Stock Exchange at prices between HK$37.20 and HK$37.50, for a volume-weighted average cost of HK$37.34 per share. • Total consideration for the buyback amounted to HK$11.20 million. • All repurchased shares were retained as treasury stock; none were cancelled. • The repurchase utilised 899,000 shares, or 1.57 % of the 57.24 million-share mandate approved on 2 June 2026.
Resulting share capital • Issued shares outstanding (excluding treasury stock) fell to 587.11 million, down 241,294 shares, or 0.04 %, from the 9 November opening balance. • Treasury shares rose to 899,000. • Total issued shares including treasury stock stood at 588.00 million as of 13 November.
Additional compliance information • A 30-day moratorium on further share issues or treasury-share sales is in place until 13 December 2026, in line with Hong Kong Listing Rule 10.06(3)(a).
The disclosures confirm that all actions were duly authorised by the board and executed in accordance with Hong Kong Stock Exchange rules and applicable regulations.
Comments